Prediction of HIV drug resistance through in silico approach

Tammanna Bhajantri S. Pushkala   

Open Access   

Published:  Jun 11, 2024

DOI: 10.7324/JABB.2024.166453

The development of drug resistance continues to be one of the most significant obstacles in the fight against human immunodeficiency virus type 1 (HIV-1) infection. Due to its exceptional replication kinetics, HIV is able to evade the selection pressure of the human immune system and the current combination drug therapy. Given that there are so many distinct mutations and mutational patterns that may confer drug resistance, it can be challenging to interpret the results of genotypic assays designed to detect them. The quantitative evaluation of resistance or susceptibility at the phenotypic level is made possible by cell culture studies. Nevertheless, the procedure is time-consuming and expensive. This study concentrates on the prediction of HIV drug resistance using an innovative “in silico” method that employs three potent resistance prediction tools: HIVdb, HIV-GRADE, and Geno2pheno[resistance]. These tools play a crucial role in the evaluation of HIV drug resistance, enabling clinicians and researchers to make informed decisions regarding antiretroviral (ARV) therapy. This study investigates the integration of these tools, emphasizing their individual strengths and collective utility in providing accurate and exhaustive HIV drug resistance predictions. Through a comprehensive analysis of genotypic data, this study seeks to improve our understanding of HIV drug resistance profiles, ultimately contributing to the optimization of ARV treatment strategies for HIV-positive individuals.

Keyword:     HIV-1 Drug resistance HIVdb HIV-GRADE Geno2pheno[resistance]


Bhajantri T, Pushkala S. Prediction of HIV drug resistance through in silico approach. J App Biol Biotech. 2024. Online First.

Copyright: Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

HTML Full Text

1. Shafer RW, Rhee S-Y, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS [Internet]. 2007;21(2):215–23.

2. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med [Internet]. 2002;347(6):385–94.

3. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181–8.

4. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet [Internet]. 2005;365(9464):1031–8.

5. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses. 2005;21:343–57.

6. Rhee S-Y. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res [Internet]. 2003;31(1):298–303.

7. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev [Internet]. 2002;15(2):247–77.

8. Hirsch MS, Brun-Vézinet F, D’Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel. JAMA [Internet]. 2000;283(18):2417.

9. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother [Internet]. 2007;59(6):1047–56.

10. Arrivé E, Newell M-L, Ekouevi DK, Chaix M-L, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol [Internet]. 2007;36(5):1009–21.

11. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV?1 infection: 2008 recommendations of an international AIDS society–USA panel. Clin Infect Dis [Internet]. 2008;47(2):266–85.

12. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15(4):119–25.

13. Kingwara L, Karanja M, Ngugi C, Kangogo G, Bera K, Kimani M, et al. From sequence data to patient result: a solution for HIV drug resistance genotyping with exatype, end to end software for pol-HIV-1 Sanger based sequence analysis and patient HIV drug resistance result generation. J Int Assoc Provid AIDS Care [Internet]. 2020;19:232595822096268.

14. Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, et al. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci USA [Internet]. 2018;115:E802–11.

15. Vercauteren J, Vandamme AM. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res [Internet]. 2006;71(2-3):335–42. antiviral.2006.05.003

16. Nayak C, Chandra I, Singh SK. An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV?1 protease variants. J Cell Biochem [Internet]. 2019;120(6):9063–81.

17. Döring M, Büch J, Friedrich G, Pironti A, Kalaghatgi P, Knops E, et al. Geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data. Nucleic Acids Res [Internet]. 2018;46:W271–7.

18. [Internet]. Rega algorithm. 2023 [cited 2023 Aug 21]. Available from:

19. [Internet]. HIV-1 genotypic drug resistance interpretation’s algorithms. 2023 [cited 2023 Aug 21]. Available from:

20. [Internet]. HIV drug resistance database. 2023 [cited 2023 Aug 21]. Available from:

21. Hiv-Grade [Internet]. 2023 [cited 2023 Aug 8]. Available from:

22. [Internet]. Geno2pheno resistance. 2023 [cited 2023 Aug 21]. Available from:

23. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis [Internet]. 2006;42(11):1608–18.

24. Tang MW, Liu TF, Shafer RW. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology [Internet]. 2012;55(2): 98–101.

25. Obermeier M, Pironti A, Berg T, Braun P, Däumer M, Eberle J, et al. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology [Internet]. 2012;55(2):102–7.

26. Beerenwinkel N. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res [Internet]. 2003;31(13):3850–5.

27. Pironti A, Walter H, Pfeifer N, Knops E, Lübke N, Büch J, et al. Determination of phenotypic resistance cutoffs from routine clinical data. J Acquir Immune Defic Syndr [Internet]. 2017;74(5):e129–37.

28. Lengauer T, Sing T. Bioinformatics-assisted anti-HIV therapy. Nat Rev Microbiol [Internet]. 2006;4(10):790–7.

29. Pironti A, Pfeifer N, Walter H, Jensen BEO, Zazzi M, Gomes P, et al. Using drug exposure for predicting drug resistance – a data-driven genotypic interpretation tool. PLoS One [Internet]. 2017;12(4):e0174992. pone.0174992

30. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the international antiviral society-USA panel. JAMA [Internet]. 2016;316(2):191.

Article Metrics
12 Views 3 Downloads 15 Total



Related Search

By author names